<DOC>
	<DOCNO>NCT02858843</DOCNO>
	<brief_summary>The purpose research study find combined therapy lumacaftor-ivacaftor affect glycemia patient cystic fibrosis .</brief_summary>
	<brief_title>The Effect Combination Lumacaftor Ivacaftor Markers Hyperglycemia</brief_title>
	<detailed_description>This single center , open label study . Patients 1 visit Diabetes Research Center ( DRC ) , Clinical Research Center ( CRC ) . The participant previously screen make sure candidate study . These patient contact prior first visit discus enrollment study . At study visit participant come CRC DRC research visit . The follow occur study visit : informed consent ; brief medical history ; weight height ; vital sign blood pressure ; blood draw DNA extraction , A1c extra research tube storage . This scheduled time convenient patient .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<criteria>1 . Age 18 year old great 2 . Patients diagnose cystic fibrosis ( CF ) , genotype homozygous Phe508del 3 . Subject start lumacaftorivacaftor clinical reason , contraindication start drug* * Contraindications take drug include abnormal liver enzyme test , renal dysfunction , pregnancy nursing mother Exclusion Criteria 1 . Does HgbA1c within 1 year prior start medication . 2 . Has combination therapy least 2 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>genetics</keyword>
</DOC>